Silence Therapeutics
SLNCF · OTC
$6.37+$0.105 (+1.68%)TodayMarket closed ·
No price history for this range.
Who owns SLNCF
Largest institutional holders, from their latest 13F filings
The 9 largest institutions hold 8.8% of SLNCF’s shares.
- Keith (Robert N)8.7%
- Ross (Iain Gladstone)0.0%
- Tooman (Craig A)0.0%
- Ede-Golightly (James Lawrence)0.0%
- Next 5 largest institutions0.0%
- All other shareholders91.2%
| Holder | Shares | % of shares |
|---|---|---|
| Keith (Robert N) | 12.29M | 8.67% |
| Ross (Iain Gladstone) | 39.94K | 0.03% |
| Tooman (Craig A) | 33.49K | 0.02% |
| Ede-Golightly (James Lawrence) | 15.00K | 0.01% |
| Romano (Steven J) | 12.99K | 0.01% |
| Lemus (David) | 7.53K | 0.01% |
| Mirae Asset Global Investments Co., Ltd. | 2.09K | 0.00% |
| Hellums (Rhonda Lynette) | 1.50K | 0.00% |
| Bellecapital AG | 2 | 0.00% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| Mirae Asset TIGER Nasdaq Bio Exchange Traded Fund(Equity) | 2.09K | 0.00% |
| Galileo Biotech Innovation Fund | 2 | 0.00% |
Short interest
Settled Sep 30, 2026
- Shares short
- 2.35K
- Days to cover
- 130.56
- % of shares outstanding
- 0.00%
- Average daily volume
- 18
- Change since last report
- +0.0%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.